• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液中性粒细胞与淋巴细胞比值与分化型甲状腺癌患者的肿瘤大小相关。

Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer.

机构信息

Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan; Mackay Medical College, New Taipei City, Taiwan.

出版信息

J Surg Oncol. 2013 Apr;107(5):493-7. doi: 10.1002/jso.23270. Epub 2012 Sep 20.

DOI:10.1002/jso.23270
PMID:22996403
Abstract

BACKGROUND AND OBJECTIVES

Inflammation has been implicated in the initiation and progression of thyroid cancer. Neutrophil-to-lymphocyte ratio (NLR) is a simple index of systemic inflammatory response, and has been shown to be a prognostic indicator in some types of cancer. The aim of this study was to examine the relationship between NLR and clinicopathological features in patients with differentiated thyroid cancer.

METHODS

Total white blood cell and differential counts of 159 patients with differentiated thyroid cancer were compared to those of 318 age- and sex-matched controls undergoing thyroidectomy for benign thyroid nodules. Clinicopathological variables, stratified by NLR tertiles, were analyzed.

RESULTS

There was no difference in NLR between patients having benign and malignant thyroid nodules (P = 0.293). Cancer patients in the higher NLR tertile had significantly larger tumor size (P = 0.004). Higher NLR was observed in patients with high American Thyroid Association (ATA) risk of recurrence.

CONCLUSIONS

High preoperative NLR was associated with increased tumor size and high ATA risk of recurrence in patients with differentiated thyroid cancer.

摘要

背景与目的

炎症与甲状腺癌的发生和进展有关。中性粒细胞与淋巴细胞比值(NLR)是全身炎症反应的一个简单指标,已被证明是某些类型癌症的预后指标。本研究旨在探讨 NLR 与分化型甲状腺癌患者临床病理特征之间的关系。

方法

比较了 159 例分化型甲状腺癌患者和 318 例因良性甲状腺结节行甲状腺切除术的年龄和性别匹配对照者的总白细胞和白细胞分类计数。分析了 NLR 三分位组的临床病理变量。

结果

良性和恶性甲状腺结节患者的 NLR 无差异(P=0.293)。 NLR 较高三分位的癌症患者肿瘤大小明显更大(P=0.004)。 NLR 较高的患者美国甲状腺协会(ATA)复发风险较高。

结论

术前高 NLR 与分化型甲状腺癌患者肿瘤增大和 ATA 高复发风险相关。

相似文献

1
Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer.血液中性粒细胞与淋巴细胞比值与分化型甲状腺癌患者的肿瘤大小相关。
J Surg Oncol. 2013 Apr;107(5):493-7. doi: 10.1002/jso.23270. Epub 2012 Sep 20.
2
The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.手术、放射性碘及外照射放疗对分化型甲状腺癌患者临床结局的影响。
Cancer. 1998 Jan 15;82(2):375-88.
3
AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States.美国分化型甲状腺癌的AMES预后指数与甲状腺切除范围
Surgery. 2004 Sep;136(3):609-16. doi: 10.1016/j.surg.2003.12.009.
4
The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study.中性粒细胞/淋巴细胞比值作为甲状腺肿中潜在乳头状微癌的标志物的意义:一项初步研究。
Am J Surg. 2013 Jun;205(6):691-6. doi: 10.1016/j.amjsurg.2012.08.006. Epub 2013 Feb 4.
5
A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems.一种用于预测分化型甲状腺癌患者预后的模型以及与其他分类系统相比的模型性能。
J Am Coll Surg. 2005 Mar;200(3):378-92. doi: 10.1016/j.jamcollsurg.2004.10.031.
6
Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?在甲状腺细针穿刺中,嗜酸性细胞病变/肿瘤比滤泡性病变/肿瘤更能预测恶性肿瘤吗?
Diagn Cytopathol. 2006 May;34(5):330-4. doi: 10.1002/dc.20440.
7
Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).分化型甲状腺癌。辅助性外照射放疗对甲状腺周围肿瘤浸润患者(pT4期)的影响。
Cancer. 1996 Jan 1;77(1):172-80. doi: 10.1002/(SICI)1097-0142(19960101)77:1<172::AID-CNCR28>3.0.CO;2-1.
8
Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.在一项大型研究人群中,家族性非髓样甲状腺癌的特征为多灶性和高复发率。
World J Surg. 2002 Aug;26(8):897-902. doi: 10.1007/s00268-002-6615-y. Epub 2002 Apr 30.
9
An Increased Neutrophil-to-Lymphocyte Ratio Predicts Incomplete Response to Therapy in Differentiated Thyroid Cancer.中性粒细胞与淋巴细胞比值升高可预测分化型甲状腺癌治疗不完全反应。
Int J Med Sci. 2018 Nov 23;15(14):1757-1763. doi: 10.7150/ijms.28498. eCollection 2018.
10
Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis.甲状腺岛状癌患者的长期预后:岛状组织学类型是预后不良的独立预测因素。
Cancer. 2002 Nov 15;95(10):2076-85. doi: 10.1002/cncr.10947.

引用本文的文献

1
Assessing the Role of Inflammatory Markers in Predicting Central Lymph Node Metastasis in Papillary Thyroid Carcinoma.评估炎症标志物在预测甲状腺乳头状癌中央淋巴结转移中的作用
Iran J Otorhinolaryngol. 2025;37(3):135-141. doi: 10.22038/ijorl.2025.84332.3840.
2
Can we diagnose noninvasive follicular thyroid neoplasm with papillary-like nuclear features before surgery?我们能否在手术前诊断出具有乳头样核特征的非侵袭性滤泡性甲状腺肿瘤?
Updates Surg. 2025 Jan 15. doi: 10.1007/s13304-025-02093-5.
3
Evaluating the Role of CBC-Derived Indices in Children with Hashimoto's Thyroiditis.
评估全血细胞计数衍生指标在桥本甲状腺炎患儿中的作用。
Diagnostics (Basel). 2024 Dec 17;14(24):2834. doi: 10.3390/diagnostics14242834.
4
Immature granulocytes and neutrophil-to-lymphocyte ratio as markers of treatment response in subacute thyroiditis.不成熟粒细胞和中性粒细胞与淋巴细胞比值作为亚急性甲状腺炎治疗反应的标志物。
Arch Endocrinol Metab. 2024 Jun 19;68:e23012. doi: 10.20945/2359-4292-2023-0012. eCollection 2024.
5
Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications.甲状腺乳头状癌的免疫微环境:免疫细胞和检查点在疾病进展中的作用及其治疗意义。
Front Immunol. 2024 Sep 3;15:1438235. doi: 10.3389/fimmu.2024.1438235. eCollection 2024.
6
Prognostic factors of papillary and follicular carcinomas based on pre-, intra-, and post-operative findings.基于术前、术中和术后发现的乳头状和滤泡状癌的预后因素。
Eur Thyroid J. 2024 Oct 4;13(5). doi: 10.1530/ETJ-24-0196. Print 2024 Oct 1.
7
High aggressiveness of papillary thyroid cancer: from clinical evidence to regulatory cellular networks.甲状腺乳头状癌的高侵袭性:从临床证据到调控细胞网络
Cell Death Discov. 2024 Aug 26;10(1):378. doi: 10.1038/s41420-024-02157-2.
8
Neutrophil diversity is associated with T-cell immunity and clinical relevance in patients with thyroid cancer.中性粒细胞多样性与甲状腺癌患者的T细胞免疫及临床相关性相关。
Cell Death Discov. 2024 May 8;10(1):222. doi: 10.1038/s41420-024-01970-z.
9
Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.炎性标志物在仑伐替尼治疗碘难治性甲状腺癌中的预后作用。
Endocrinol Metab (Seoul). 2024 Apr;39(2):334-343. doi: 10.3803/EnM.2023.1854. Epub 2024 Apr 4.
10
Harnessing Immunity to Treat Advanced Thyroid Cancer.利用免疫疗法治疗晚期甲状腺癌。
Vaccines (Basel). 2023 Dec 30;12(1):45. doi: 10.3390/vaccines12010045.